- Glenmark receives acceptance from U.S. FDA on its IND application for GRC 54276 to proceed with a Phase 1/2, first-in-human clinical study of the molecule for the treatment of patients with advanced solid tumors and lymphomas
- Glenmark and Cediprof Announce Exclusive Distribution Agreement in the United States for US FDA Approved Mixed Amphetamines Immediate-Release Tablets
Key statistics
On Friday, Glenmark Pharmaceuticals Ltd (GLENMARK:NSI) closed at 614.15, -2.49% below its 52-week high of 629.85, set on May 19, 2023.
52-week range
Open | 613.85 |
---|---|
High | 615.35 |
Low | 608.50 |
Bid | -- |
Offer | -- |
Previous close | 614.15 |
Average volume | 1.75m |
---|---|
Shares outstanding | 282.17m |
Free float | 134.99m |
P/E (TTM) | 58.32 |
Market cap | 173.29bn INR |
EPS (TTM) | 10.53 INR |
Annual div (ADY) | 2.50 INR |
---|---|
Annual div yield (ADY) | 0.41% |
Div ex-date | Sep 12 2022 |
Div pay-date | Oct 27 2022 |
Data delayed at least 15 minutes, as of Jun 02 2023 11:10 BST.
More ▼